Glucagon as a target for the treatment of Type 2 diabetes
- 10 June 2005
- journal article
- review article
- Published by Informa Healthcare in Emerging Therapeutic Targets
- Vol. 9 (3) , 593-600
- https://doi.org/10.1517/14728222.9.3.593
Abstract
Glucagon is the key counter-regulatory hormone that opposes the action of insulin. In states of relative hypoglycaemia, glucagon acts to increase blood glucose by stimulating hepatic glycogen breakdown and gluconeogenesis to achieve euglycaemia. Type 2 diabetes is characterised by inappropriate regulation of hepatic glucose production, which is due, at least in part, to an imbalance in the bihormonal relationship between plasma levels of glucagon and insulin. The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia. In recent years, the development of GCGR antisense oligonucleotides and small molecular weight GCGR antagonists have been pursued as possible therapeutic agents to target glucagon action as a treatment for Type 2 diabetes.Keywords
This publication has 48 references indexed in Scilit:
- Differential regional metabolism of glucagon in anesthetized pigsAmerican Journal of Physiology-Endocrinology and Metabolism, 2003
- Abrogation of Protein Convertase 2 Activity Results in Delayed Islet Cell Differentiation and Maturation, Increased α-Cell Proliferation, and Islet NeogenesisEndocrinology, 2003
- Glucagon Replacement via Micro-Osmotic Pump Corrects Hypoglycemia and α-Cell Hyperplasia in Prohormone Convertase 2 Knockout MiceDiabetes, 2002
- Adrenaline Stimulates Glucagon Secretion in Pancreatic A-Cells by Increasing the Ca2+ Current and the Number of Granules Close to the L-Type Ca2+ ChannelsThe Journal of general physiology, 1997
- Role of the prohormone convertase PC2 in the processing of proglucagon to glucagonFEBS Letters, 1997
- Differential Processing of Proglucagon by the Subtilisin-like Prohormone Convertases PC2 and PC3 to Generate either Glucagon or Glucagon-like PeptideJournal of Biological Chemistry, 1995
- Compartmental modeling of glucagon kinetics in the conscious dogMetabolism, 1995
- Contribution to Postprandial Hyperglycemia and Effect on Initial Splanchnic Glucose Clearance of Hepatic Glucose Cycling in Glucose-Intolerant or NIDDM PatientsDiabetes, 1991
- Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptakeMetabolism, 1989
- Differences in the hepatic and renal extraction of insulin and glucagon in the dog: evidence for saturability of insulin metabolismActa Endocrinologica, 1983